Imaging-guided targeted radionuclide tumor therapy: From concept to clinical translation
Abstract
Since the first introduction of sodium iodide I-131 for use with thyroid patients almost 80 years ago, more than 50 radiopharmaceuticals have reached the markets for a wide range of diseases, especially cancers. The nuclear medicine paradigm also shifts from solely molecular imaging or radionuclide therapy to imaging-guided radionuclide therapy, which is deemed a vital component of precision cancer therapy and an emerging medical modality for personalized medicine. The imaging-guided radionuclide therapy highlights the systematic integration of targeted nuclear diagnostics and radionuclide therapeutics. Regarding this, nuclear imaging serves to "visualize" the lesions and guide the therapeutic strategy, followed by administration of a precise patient specific dose of radiotherapeutics for treatment according to the absorbed dose to different organs and tumors calculated by dosimetry tools, and finally repeated imaging to predict the prognosis. This strategy leads to significantly enhanced therapeutic efficacy, improved patient outcomes, and manageable adverse events. In this review, we provide an overview of imaging-guided targeted radionuclide therapy for different tumors such as advanced prostate cancer and neuroendocrine tumors, with a focus on development of new radioligands and their preclinical and clinical results, and further discuss about challenges and future perspectives.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
177Lu-PSMA-617 is a potent radiolabelled antibody for prostate cancer, capitalizing on PSMA overexpression.
“In prostate cancer, radiolabelled antibodies like 177Lu-PSMA-617 have emerged as potent tools, capitalizing on the overexpression of prostate-specific membrane antigen (PSMA) in prostate cancer cells [98]”
From Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation (2024) · cites this paper as [98]
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699 · see citing works
The biology and function of fibroblasts in cancer
Kalluri, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.73 · Cited by 4,366 · see citing works
A framework for advancing our understanding of cancer-associated fibroblasts
Sahai, E., Astsaturov, I., Cukierman, E., DeNardo, D. G., Egeblad, M., Evans, R. M., Fearon, D., Greten, F. R., Hingorani, S. R., Hunter, T., et al. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0238-1 · Cited by 3,863 · see citing works
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308 · see citing works
Hofman, M. S., Lawrentschuk, N., Francis, R. J., Tang, C., Vela, I., Thomas, P. A., Rutherford, N. K., Martin, J. M., Frydenberg, M., Ramdave, S., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30314-7 · Cited by 2,067 · see citing works
68 Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer
Kratochwil, C., Flechsig, P., Lindner, T., Abderrahim, L., Altmann, A., Mier, W., Adeberg, S., Rathke, H. G., Röhrich, M., Winter, H., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.227967 · Cited by 1,478 · see citing works
SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action
Bauer, W., Briner, U., Doepfner, W., Haller, R., Huguenin, R., Marbach, P., Petcher, T. J., & Pless, J. (1982) · Life Sciences · doi:10.1016/0024-3205(82)90087-x · Cited by 1,332 · see citing works
Hofman, M. S., Violet, J. A., Hicks, R. J., Ferdinandus, J., Thang, S. P., Akhurst, T. J., Iravani, A., Kong, G., Kumar, A. S. R., Murphy, D. G., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30198-0 · Cited by 1,184 · see citing works
Kratochwil, C., Bruchertseifer, F., Giesel, F. L., Weis, M., Verburg, F. A., Mottaghy, F. M., Kopka, K., Apostolidis, C., Haberkorn, U., & Morgenstern, A. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178673 · Cited by 1,163 · see citing works
Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α
Kraman, M., Bambrough, P. J., Arnold, J. N., Roberts, E. W., Magiera, L., Jones, J. O., Gopinathan, A., Tuveson, D. A., & Fearon, D. T. (2010) · Science · doi:10.1126/science.1195300 · Cited by 1,134 · see citing works
Reubi, J. C., Schär, J.-C., Waser, B., Wenger, S., Heppeler, A., Schmitt, J. S., & Mäcke, H. R. (2000) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050034 · Cited by 1,127 · see citing works
Radiopharmaceutical therapy in cancer: clinical advances and challenges
Sgouros, G., Bodei, L., McDevitt, M. R., & Nedrow, J. R. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0073-9 · Cited by 980 · see citing works
Lindner, T., Loktev, A., Altmann, A., Giesel, F. L., Kratochwil, C., Debus, J., Jäger, D., Mier, W., & Haberkorn, U. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.210443 · Cited by 947 · see citing works
Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer
Ghosh, A., & Heston, W. D. W. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10661 · Cited by 883 · see citing works
Rahbar, K., Ahmadzadehfar, H., Kratochwil, C., Haberkorn, U., Schäfers, M. A., Essler, M., Baum, R. P., Kulkarni, H., Schmidt, M. C., Drzezga, A. E., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.183194 · Cited by 849 · see citing works
Chang, S. S., Reuter, V. E., Heston, W. D. W., Bander, N. H., Grauer, L. S., & Gaudin, P. B. (1999) · PubMed · Cited by 807 · see citing works
A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts
Loktev, A., Lindner, T., Mier, W., Debus, J., Altmann, A., Jäger, D., Giesel, F. L., Kratochwil, C., Barthe, P., Roumestand, C., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.210435 · Cited by 784 · see citing works
Albumin-based drug delivery: harnessing nature to cure disease
Larsen, M. T., Kuhlmann, M., Hvam, M. L., & Howard, K. A. (2016) · Molecular and Cellular Therapies · doi:10.1186/s40591-016-0048-8 · Cited by 690 · see citing works
Imhof, A., Brunner, P., Marincek, N., Briel, M., Schindler, C., Rasch, H. F., Mäcke, H. R., Rochlitz, C. F., Müller‐Brand, J., & Walter, M. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.7873 · Cited by 638 · see citing works
Benešová, M., Schäfer, M. K.-H., Bauder‐Wüst, U., Afshar‐Oromieh, A., Kratochwil, C., Mier, W., Haberkorn, U., Kopka, K., & Eder, M. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.147413 · Cited by 621 · see citing works
Current use of PSMA–PET in prostate cancer management
Maurer, T., Eiber, M. J., Schwaiger, M., & Gschwend, J. E. (2016) · Nature Reviews Urology · doi:10.1038/nrurol.2016.26 · Cited by 613 · see citing works
Poly(ADP-ribose) polymerase inhibition: past, present and future
Curtin, N. J., & Szabó, C. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0076-6 · Cited by 576 · see citing works
Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor Retention
Loktev, A., Lindner, T., Burger, E.-M., Altmann, A., Giesel, F. L., Kratochwil, C., Debus, J., Marmé, F., Jäger, D., Mier, W., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.224469 · Cited by 560 · see citing works
Weineisen, M., Schottelius, M., Šimeček, J., Baum, R. P., Yıldız, A., Beykan, S., Kulkarni, H., Laßmann, M., Klette, I., Eiber, M. J., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.158550 · Cited by 540 · see citing works
Baum, R. P., Kulkarni, H., Schuchardt, C., Singh, A., Wirtz, M., Wiessalla, S., Schottelius, M., Müeller, D., Klette, I., & Wester, H. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.168443 · Cited by 526 · see citing works
Structure of the agonist-bound neurotensin receptor
White, J. F., Noinaj, N., Shibata, Y., Love, J. D., Kloss, B., Xu, F., Gvozdenovic‐Jeremic, J., Shah, P., Shiloach, J., Tate, C. G., et al. (2012) · Nature · doi:10.1038/nature11558 · Cited by 511 · see citing works
Kim, G. S., Ison, G., McKee, A. E., Zhang, H., Tang, S.-H., Gwise, T., Sridhara, R., Lee, E. Y., Tzou, A., Philip, R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0887 · Cited by 508 · see citing works
Albumin Binding as a General Strategy for Improving the Pharmacokinetics of Proteins
Dennis, M. S., Zhang, M., Meng, Y., Kadkhodayan, M., Kirchhofer, D., Combs, D., & Damico, L. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205854200 · Cited by 508 · see citing works
Fibroblast heterogeneity: implications for human disease
Lynch, M. D., & Watt, F. M. (2018) · Journal of Clinical Investigation · doi:10.1172/jci93555 · Cited by 490 · see citing works
ImmunoPET: Concept, Design, and Applications
Wei, W., Rosenkrans, Z. T., Liu, J., Huang, G., Luo, Q., & Cai, W. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00738 · Cited by 483 · see citing works
Kratochwil, C., Bruchertseifer, F., Rathke, H. G., Hohenfellner, M., Giesel, F. L., Haberkorn, U., & Morgenstern, A. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.203539 · Cited by 429 · see citing works
Radiometals for Combined Imaging and Therapy
Cutler, C. S., Hennkens, H. M., Sisay, N., et al. (2012) · Chemical Reviews · doi:10.1021/cr3003104 · Cited by 397 · see citing works
Chen, Y., Pullambhatla, M., Foss, C. A., Byun, Y., Nimmagadda, S., Senthamizhchelvan, S., Sgouros, G., Mease, R. C., & Pomper, M. G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1357 · Cited by 393 · see citing works
Medical imaging and nuclear medicine: a Lancet Oncology Commission
Hricak, H., Abdel–Wahab, M., Atun, R. A., Mikhail-Lette, M., Páez, D., Brink, J. A., Donoso, L., Frija, G. G., Hierath, M., Holmberg, O., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30751-8 · Cited by 382 · see citing works
Baum, R. P., Schuchardt, C., Singh, A., Chantadisai, M., Robiller, F., Zhang, J., Müeller, D., Eismant, A., Almaguel, F. A., Zboralski, D., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.259192 · Cited by 373 · see citing works
Zechmann, C. M., Afshar‐Oromieh, A., Armor, T., Stubbs, J. B., Mier, W., Hadaschik, B. A., Joyal, J. L., Kopka, K., Debus, J., Babich, J. W., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2713-y · Cited by 359 · see citing works
Hu, K., Xie, L., Zhang, Y., Hanyu, M., Yang, Z., Nagatsu, K., Suzuki, H., Ouyang, J., Ji, X., Wei, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16513-0 · Cited by 347 · see citing works
Self-citationRadiotheranostics: a roadmap for future development
Herrmann, K., Schwaiger, M., Lewis, J. S., Solomon, S. B., McNeil, B. J., Baumann, M. A., Gambhir, S. S., Hricak, H., & Weissleder, R. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30821-6 · Cited by 332 · see citing works
Hillier, S., Maresca, K. P., Femia, F. J., Marquis, J. C., Foss, C. A., Nguyen, N. H., Zimmerman, C. N., Barrett, J. A., Eckelman, W. C., Pomper, M. G., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1682 · Cited by 318 · see citing works
Giesel, F. L., Adeberg, S., Syed, M., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.245084 · Cited by 315 · see citing works
Wild, D., Schmitt, J. S., Ginj, M., et al. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-003-1255-5 · Cited by 310 · see citing works
Watabe, T., Liu, Y., Kaneda‐Nakashima, K., Shirakami, Y., Lindner, T., Ooe, K., Toyoshima, A., Nagata, K., Shimosegawa, E., Haberkorn, U., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.233122 · Cited by 309 · see citing works
Radioactive Transition Metals for Imaging and Therapy
Boros, E., & Packard, A. B. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00281 · Cited by 300 · see citing works
Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase
Davis, M. I., Bennett, M. J., Thomas, L. M., & Bjorkman, P. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502101102 · Cited by 296 · see citing works
Violet, J., Sandhu, S., Iravani, A., Ferdinandus, J., Thang, S.-P., Kong, G., Kumar, A. R., Akhurst, T., Pattison, D., Beaulieu, A., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.236414 · Cited by 292 · see citing works
Herrmann, K., Schottelius, M., Lapa, C., Osl, T., Poschenrieder, A., Hänscheid, H., Lückerath, K., Schreder, M., Bluemel, C., Knott, M., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.167361 · Cited by 278 · see citing works
Somatostatin receptor antagonists for imaging and therapy.
Fani, M., Nicolas, G. P., & Wild, D. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.186783 · Cited by 274 · see citing works
Deppen, S. A., Blume, J. D., Bobbey, A. J., Shah, C., Graham, M. M., Lee, P. J., Delbeke, D., & Walker, R. C. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.165803 · Cited by 267 · see citing works
Radiobiologic principles in radionuclide therapy.
Kassis, A. I., & Adelstein, S. J. (2005) · PubMed · Cited by 265 · see citing works
Fani, M., Pozzo, L. D., Abiraj, K., Mansi, R., Tamma, M. L., Cescato, R., Waser, B., Weber, W., Reubi, J. C., & Maëcke, H. R. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.087999 · Cited by 262 · see citing works
Radiohalogens for imaging and therapy
Adam, M. J., & Wilbur, D. S. (2004) · Chemical Society Reviews · doi:10.1039/b313872k · Cited by 260 · see citing works
Garske-Román, U., Sandström, M., Fröss Baron, K., Lundin, L., Hellman, P., Welin, S., Johansson, S., Khan, T., Lundqvist, H., Eriksson, B., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-3945-z · Cited by 254 · see citing works
Li, Z., Cai, W., Cao, Q., Chen, K., Wu, Z., He, L., & Chen, X. S. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.039859 · Cited by 248 · see citing works
Johnbeck, C. B., Knigge, U., Loft, A., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.180430 · Cited by 243 · see citing works
18 F‐Labeling of Peptides by means of an Organosilicon‐Based Fluoride Acceptor
Schirrmacher, R., Bradtmöller, G., Schirrmacher, E., et al. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200600795 · Cited by 234 · see citing works
Introduction to Radiobiology of Targeted Radionuclide Therapy
Pouget, J., Lozza, C., Deshayes, E., Boudousq, V., & Navarro‐Teulon, I. (2015) · Frontiers in Medicine · doi:10.3389/fmed.2015.00012 · Cited by 233 · see citing works
Benešová, M., Bauder‐Wüst, U., Schäfer, M. K.-H., Klika, K. D., Mier, W., Haberkorn, U., Kopka, K., & Eder, M. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01210 · Cited by 230 · see citing works
Patel, R. B., Hernandez, R. T., Carlson, P. M., Grudzinski, J. J., Bates, A. M., Jagodinsky, J. C., Erbe, A. K., Marsh, I. R., Arthur, I. S., Aluicio‐Sarduy, E., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb3631 · Cited by 229 · see citing works
PET of CXCR4 Expression by a 68Ga-Labeled Highly Specific Targeted Contrast Agent
Gourni, E., Demmer, O., Schottelius, M., et al. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.098798 · Cited by 228 · see citing works
Current and Emerging Clinical Applications of PSMA PET Diagnostic Imaging for Prostate Cancer
Farolfi, A., Calderoni, L., Mattana, F., Mei, R., Telo, S., Fanti, S., & Castellucci, P. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.257238 · Cited by 222 · see citing works
Philipp‐Abbrederis, K., Herrmann, K., Knop, S. T., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404698 · Cited by 221 · see citing works
PSMA Ligands for PET Imaging of Prostate Cancer
Schwarzenboeck, S. M., Rauscher, I., Bluemel, C., Fendler, W. P., Rowe, S. P., Pomper, M. G., Asfhar-Oromieh, A., Herrmann, K., & Eiber, M. J. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.191031 · Cited by 219 · see citing works
Wild, D., Bomanji, J. B., Benkert, P., Maëcke, H. R., Ell, P. J., Reubi, J. C., & Caplin, M. E. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.111724 · Cited by 218 · see citing works
de Jong, M., Bakker, W. H., Krenning, E. P., Breeman, W. A. P., van der Pluijm, M. E., Bernard, B. F., Visser, T. J., Jermann, E., Béhé, M. P., Powell, P., et al. (1997) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/bf00881807 · Cited by 215 · see citing works
Ballal, S., Yadav, M. P., Bal, C., Sahoo, R. K., & Tripathi, M. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04567-2 · Cited by 215 · see citing works
Okamoto, S., Thieme, A., Allmann, J., D’Alessandria, C., Maurer, T., Retz, M., Tauber, R., Heck, M. M., Wester, H.-J., Tamaki, N., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178483 · Cited by 213 · see citing works
Smith-Jones, P. M., Vallabahajosula, S., Goldsmith, S. J., et al. (2000) · PubMed · Cited by 208 · see citing works
Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours
Mansi, R., Wang, X., Forrer, F., et al. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1596-9 · Cited by 205 · see citing works
Talazoparib: First Global Approval
Hoy, S. M. (2018) · Drugs · doi:10.1007/s40265-018-1026-z · Cited by 205 · see citing works
Delpassand, E. S., Tworowska, I., Esfandiari, R., Torgue, J., Hurt, J., Shafie, A., & Núñez, R. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263230 · Cited by 199 · see citing works
O’Keefe, D. S., Bacich, D. J., Huang, S. S.-L., & Heston, W. D. W. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.203877 · Cited by 197 · see citing works
Liu, Y., Watabe, T., Kaneda‐Nakashima, K., Shirakami, Y., Naka, S., Ooe, K., Toyoshima, A., Nagata, K., Haberkorn, U., Kratochwil, C., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05554-2 · Cited by 197 · see citing works
Pandit-Taskar, N. D., O’Donoghue, J. A., Durack, J. C., Lyashchenko, S. K., Cheal, S. M., Beylergil, V., Lefkowitz, R. A., Carrasquillo, J. A., Martinez, D. F., Fung, A. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0552 · Cited by 195 · see citing works
Design and Development of 99m Tc-Labeled FAPI Tracers for SPECT Imaging and 188 Re Therapy
Lindner, T., Altmann, A., Krämer, S., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.239731 · Cited by 194 · see citing works
First Clinical Results for PSMA-Targeted α-Therapy Using 225Ac-PSMA-I&T in Advanced-mCRPC Patients
Zacherl, M. J., Gildehaus, F. J., Mittlmeier, L. M., Böning, G., Gosewisch, A., Wenter, V., Unterrainer, M., Schmidt-Hegemann, N.-S., Belka, C., Kretschmer, A., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.251017 · Cited by 192 · see citing works
Niraparib: First Global Approval
Scott, L. J. (2017) · Drugs · doi:10.1007/s40265-017-0752-y · Cited by 186 · see citing works
Clinical PET of Neuroendocrine Tumors Using64Cu-DOTATATE: First-in-Humans Study
Pfeifer, A., Knigge, U., Mortensen, J., Oturai, P., Berthelsen, A. K., Loft, A., Binderup, T., Rasmussen, P., Elema, D. R., Klausen, T. L., et al. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.101469 · Cited by 185 · see citing works
[68Ga]Ga-DOTA-TOC: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging
Hennrich, U., & Benešová, M. (2020) · Pharmaceuticals · doi:10.3390/ph13030038 · Cited by 184 · see citing works
First Clinical Evidence That Imaging with Somatostatin Receptor Antagonists Is Feasible
Wild, D., Fani, M., Béhé, M. P., Brink, I., Rivier, J., Reubi, J. C., Maëcke, H. R., & Weber, W. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.088922 · Cited by 183 · see citing works
Targeted radionuclide therapy in combined-modality regimens
Gill, M. R., Falzone, N., Du, Y., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30379-0 · Cited by 181 · see citing works
Xu, M., Zhang, P., Ding, J., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262533 · Cited by 180 · see citing works
Giesel, F. L., Will, L., Lawal, I. O., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.204669 · Cited by 179 · see citing works
Mansi, R., Wang, X., Forrer, F., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3145 · Cited by 178 · see citing works
Balasubramaniam, S., Beaver, J. A., Horton, S. L., Fernandes, L. L., Tang, S. W., Horne, H. N., Liu, J., Liu, C., Schrieber, S. J., Yu, J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1337 · Cited by 173 · see citing works
Unexpected Sensitivity of sst<sub>2</sub> Antagonists to N-Terminal Radiometal Modifications
Fani, M., Braun, F., Waser, B., Beetschen, K., Cescato, R., Erchegyi, J., Rivier, J. E., Weber, W. A., Maecke, H. R., & Reubi, J. C. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.102764 · Cited by 172 · see citing works
Zhao, L., Niu, B., Fang, J., Pang, Y., Li, S., Xie, C., Sun, L., Zhang, X., Guo, Z., Lin, Q., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263016 · Cited by 172 · see citing works
Toms, J., Kogler, J., Maschauer, S., Daniel, C., Schmidkonz, C., Kuwert, T., & Prante, O. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.242958 · Cited by 169 · see citing works
Detection and analysis of ?-catenin mutations in prostate cancer
Chesire, D. R., Ewing, C. M., Sauvageot, J., Bova, G. S., & Isaacs, W. B. (2000) · The Prostate · doi:10.1002/1097-0045(20001201)45:4 · Cited by 168 · see citing works
Positron emission tomography (PET) imaging with (18)F-based radiotracers.
Alauddin, M. M. (2012) · PubMed · Cited by 165 · see citing works
Millul, J., Bassi, G., Mock, J., Elsayed, A., Pellegrino, C. E., Zana, A., Plaza, S. D., Nadal, L., Gloger, A., Schmidt, E., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2101852118 · Cited by 165 · see citing works
Decristoforo, C., Meléndez‐Alafort, L., Sosabowski, J. K., et al. (2000) · PubMed · Cited by 161 · see citing works
Zhang, A. X., Murelli, R. P., Bařinka, C., et al. (2010) · Journal of the American Chemical Society · doi:10.1021/ja104591m · Cited by 160 · see citing works
PSMA as a target for radiolabelled small molecules
Eder, M., Eisenhut, M., Babich, J. W., & Haberkorn, U. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2374-2 · Cited by 149 · see citing works
Umbricht, C. A., Benešová, M., Schibli, R., et al. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00152 · Cited by 149 · see citing works
Hicks, R. J., Jackson, P. A., Kong, G., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.217745 · Cited by 149 · see citing works
Quantitative 177 Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system
Beauregard, J., Hofman, M. S., Pereira, J. M., Eu, P., & Hicks, R. J. (2011) · Cancer Imaging · doi:10.1102/1470-7330.2011.0012 · Cited by 147 · see citing works
Kurth, J., Krause, B. J., Schwarzenböck, S. M., Bergner, C., Hakenberg, O. W., & Heuschkel, M. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04504-3 · Cited by 147 · see citing works
Clinical Use of Monoclonal Antibody HuJ591 Therapy: Targeting Prostate Specific Membrane Antigen
Nanus, D. M., Milowsky, M. I., Kostakoğlu, L., et al. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000095151.97404.7c · Cited by 145 · see citing works
Targeted alpha therapy of mCRPC: Dosimetry estimate of 213Bismuth-PSMA-617
Kratochwil, C., Schmidt, K. F., Afshar‐Oromieh, A., Bruchertseifer, F., Rathke, H. G., Morgenstern, A., Haberkorn, U., & Giesel, F. L. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3817-y · Cited by 141 · see citing works
Dalm, S. U., Nonnekens, J., Doeswijk, G. N., de Blois, E., van Gent, D. C., Konijnenberg, M., & de Jong, M. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.167007 · Cited by 137 · see citing works
Wang, S., Zhou, X., Xu, X., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05470-5 · Cited by 136 · see citing works
Schottelius, M., Osl, T., Poschenrieder, A., Hoffmann, F., Beykan, S., Hänscheid, H., Schirbel, A., Buck, A. K., Kropf, S., Schwaiger, M., et al. (2017) · Theranostics · doi:10.7150/thno.19119 · Cited by 135 · see citing works
Radiotheranostics in Cancer Diagnosis and Management
Jadvar, H., Chen, X. S., Cai, W., & Mahmood, U. (2018) · Radiology · doi:10.1148/radiol.2017170346 · Cited by 135 · see citing works
Bench to Bedside: Albumin Binders for Improved Cancer Radioligand Therapies
Lau, J., Jacobson, O., Niu, G., Lin, K., Bénard, F., & Chen, X. S. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00919 · Cited by 134 · see citing works
Tagawa, S. T., Vallabhajosula, S., Christos, P. J., Jhanwar, Y. S., Batra, J. S., Lam, L., Osborne, J. R., Beltran, H., Molina, A. M., Goldsmith, S. J., et al. (2019) · Cancer · doi:10.1002/cncr.32072 · Cited by 134 · see citing works
Zang, J., Fan, X., Wang, H., Liu, Q., Wang, J., Li, H. Y., Li, F., Jacobson, O., Niu, G., Zhu, Z., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4096-y · Cited by 132 · see citing works
Ballal, S., Yadav, M. P., Kramer, V., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04990-w · Cited by 127 · see citing works
Baum, R. P., Zhang, J., Schuchardt, C., Müller, D., & Mäcke, H. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.258889 · Cited by 127 · see citing works
Hammer, S., Hagemann, U. B., Zitzmann-Kolbe, S., Larsen, A., Ellingsen, C., Géraudie, S., Grant, D., Indrevoll, B., Smeets, R., von Ahsen, O., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2268 · Cited by 126 · see citing works
Somatostatin Receptors as Targets for Nuclear Medicine Imaging and Radionuclide Treatment
Maëcke, H. R., & Reubi, J. C. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.084236 · Cited by 124 · see citing works
Thermodynamics of Multivalent Interactions: Influence of the Linker
Kane, R. S. (2010) · Langmuir · doi:10.1021/la9047193 · Cited by 123 · see citing works
Borgna, F., Haller, S., Rodríguez, J. M. M., Ginj, M., Grundler, P. V., Zeevaart, J. R., Köster, U., Schibli, R., van der Meulen, N. P., & Müller, C. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05564-0 · Cited by 123 · see citing works
Moon, E. S., Elvas, F., Vliegen, G., Lombaerde, S. D., Vangestel, C., Bruycker, S. D., Bracke, A., Eppard, E., Greifenstein, L., Klasen, B., et al. (2020) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-020-00102-z · Cited by 122 · see citing works
68Ga-DOTATOC Imaging of Neuroendocrine Tumors: A Systematic Review and Metaanalysis
Graham, M. M., Gu, X., Ginader, T., Breheny, P. J., & Sunderland, J. J. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.191197 · Cited by 121 · see citing works
Renal uptake and metabolism of radiopharmaceuticals derived from peptides and proteins
Akizawa, H., Uehara, T., & Arano, Y. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.04.005 · Cited by 119 · see citing works
Neurotensin Receptor 1 Determines the Outcome of Non–Small Cell Lung Cancer
Alifano, M., Souazé, F., Dupouy, S., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0659 · Cited by 119 · see citing works
68 Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Glioblastoma
Lapa, C., Lückerath, K., Kleinlein, I., et al. (2016) · Theranostics · doi:10.7150/thno.13986 · Cited by 117 · see citing works
Targeted Radionuclide Therapy: A Historical and Personal Review
Goldsmith, S. J. (2019) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2019.07.006 · Cited by 117 · see citing works
THE ALBUMIN-BINDING DOMAIN AS A SCAFFOLD FOR PROTEIN ENGINEERING
Nilvebrant, J., & Hober, S. (2013) · Computational and Structural Biotechnology Journal · doi:10.5936/csbj.201303009 · Cited by 116 · see citing works
Somatostatin receptor-targeted anti-cancer therapy.
Sun, L.-C., & Coy, D. (2011) · Current Drug Delivery · doi:10.2174/156720111793663633 · Cited by 115 · see citing works
Wang, Z., Tian, R., Niu, G., Ma, Y., Lang, L., Szajek, L. P., Kiesewetter, D. O., Jacobson, O., & Chen, X. S. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00556 · Cited by 115 · see citing works
Kuo, H., Merkens, H., Zhang, Z., Uribe, C., Lau, J., Zhang, C., Colpo, N., Lin, K., & Bénard, F. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00720 · Cited by 115 · see citing works
Tchou, J. C., Zhang, P. J., Bi, Y., Satija, C., Marjumdar, R., Stephen, T. L., Lo, A., Chen, H., Mies, C., June, C. H., et al. (2013) · Human Pathology · doi:10.1016/j.humpath.2013.06.016 · Cited by 112 · see citing works
Baum, R. P., Kluge, A., Kulkarni, H., et al. (2016) · Theranostics · doi:10.7150/thno.13702 · Cited by 110 · see citing works
Niedermoser, S., Chin, J., Wängler, C., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.149583 · Cited by 109 · see citing works
Targeted Radionuclide Therapy of Prostate Cancer—From Basic Research to Clinical Perspectives
Czerwińska, M., Bilewicz, A., Kruszewski, M. K., Węgierek-Ciuk, A., & Lankoff, A. (2020) · Molecules · doi:10.3390/molecules25071743 · Cited by 109 · see citing works
Cescato, R., Waser, B., Fani, M., & Reubi, J. C. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.095778 · Cited by 108 · see citing works
Radiation doses from 161Tb and 177Lu in single tumour cells and micrometastases
Alcocer‐Ávila, M., Ferreira, A., Quinto, M. A., Morgat, C., Hindié, E., & Champion, C. (2020) · EJNMMI Physics · doi:10.1186/s40658-020-00301-2 · Cited by 108 · see citing works
Evans Blue Attachment Enhances Somatostatin Receptor Subtype-2 Imaging and Radiotherapy
Tian, R., Jacobson, O., Niu, G., Kiesewetter, D. O., Wang, Z., Zhu, G., Ma, Y., Liu, G., & Chen, X. S. (2017) · Theranostics · doi:10.7150/thno.23491 · Cited by 107 · see citing works
Zhang, J., Wang, H., Jacobson, O., Cheng, Y., Niu, G., Li, F., Bai, C., Zhu, Z., & Chen, X. S. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.209841 · Cited by 104 · see citing works
Fibroblast Activation Protein Inhibitor PET/CT
Sharma, P., Singh, S. S., & Gayana, S. (2020) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000003489 · Cited by 104 · see citing works
Targeted Brain Tumor Radiotherapy Using an Auger Emitter
Pirovano, G., Jannetti, S. A., Carter, L. M., Sadique, A., Kossatz, S., Guru, N., França, P. D. D. S., Maeda, M., Zeglis, B. M., Lewis, J. S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2440 · Cited by 103 · see citing works
Paterson, B. M., Roselt, P. D., Denoyer, D., et al. (2013) · Dalton Transactions · doi:10.1039/c3dt52647j · Cited by 101 · see citing works
Schottelius, M., Wirtz, M., Eiber, M. J., et al. (2015) · EJNMMI Research · doi:10.1186/s13550-015-0147-6 · Cited by 101 · see citing works
Rapid Cu-Catalyzed [211At]Astatination and [125I]Iodination of Boronic Esters at Room Temperature
Reilly, S. W., Makvandi, M., Xu, K., et al. (2018) · Organic Letters · doi:10.1021/acs.orglett.8b00232 · Cited by 101 · see citing works
18F-labeled tracers targeting fibroblast activation protein
Lindner, T., Altmann, A., Giesel, F. L., et al. (2021) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-021-00144-x · Cited by 100 · see citing works
Kuyumcu, S., Kovan, B., Şanlı, Y., Büyükkaya, F., Şimşek, D. H., Özkan, Z. G., Işık, E. G., Ekenel, M., & Türkmen, C. (2021) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000003667 · Cited by 99 · see citing works
Makvandi, M., Xu, K., Lieberman, B. P., Anderson, R., Effron, S. S., Winters, H. D., Zeng, C., McDonald, E. S., Pryma, D. A., Greenberg, R. A., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0416 · Cited by 98 · see citing works
Khreish, F., Ghazal, Z., Marlowe, R. J., Rosar, F., Sabet, A., Maus, S., Linxweiler, J., Bartholomä, M. D., & Ezziddin, S. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05525-7 · Cited by 98 · see citing works
Rupp, N. J., Umbricht, C. A., Pizzuto, D. A., Lenggenhager, D. M., Töpfer, A., Müller, J., Muehlematter, U. J., Ferraro, D. A., Messerli, M., Morand, G. B., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.222307 · Cited by 97 · see citing works
Delpassand, E. S., Ranganathan, D., Wagh, N. K., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.236091 · Cited by 96 · see citing works
Baum, R. P., Singh, A., Schuchardt, C., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.193847 · Cited by 94 · see citing works
Kuo, H., Lin, K., Zhang, Z., Uribe, C., Merkens, H., Zhang, C., & Bénard, F. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.250738 · Cited by 94 · see citing works
Pauwels, E., Cleeren, F., Tshibangu, T., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04918-4 · Cited by 93 · see citing works
Non-invasive PET Imaging of PARP1 Expression in Glioblastoma Models
Carney, B. D., Carlucci, G., Salinas, B., Gialleonardo, V. D., Kossatz, S., Vansteene, A., Longo, V. A., Bolaender, A., Chiosis, G., Keshari, K. R., et al. (2015) · Molecular Imaging and Biology · doi:10.1007/s11307-015-0904-y · Cited by 91 · see citing works
Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer
Donin, N. M., & Reiter, R. E. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.191874 · Cited by 91 · see citing works
Yahyapour, R., Motevaseli, E., Rezaeyan, A., et al. (2017) · Current Radiopharmaceuticals · doi:10.2174/1874471011666171229123130 · Cited by 91 · see citing works
Combination Strategies to Improve Targeted Radionuclide Therapy
Chan, T. G., O’Neill, E., Habjan, C., & Cornelissen, B. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.248062 · Cited by 91 · see citing works
Fatty acid-conjugated radiopharmaceuticals for fibroblast activation protein-targeted radiotherapy
Zhang, P., Xu, M., Ding, J., Chen, J., Zhang, T., Huo, L., & Liu, Z. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05591-x · Cited by 91 · see citing works
Rottenburger, C., Nicolas, G. P., McDougall, L., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.233031 · Cited by 90 · see citing works
PSMA-targeting agents for radio- and fluorescence-guided prostate cancer surgery
Derks, Y. H. W., Löwik, D. W. P. M., Sedelaar, J. P. M., Gotthardt, M., Boerman, O. C., Rijpkema, M., Lütje, S., & Heskamp, S. (2019) · Theranostics · doi:10.7150/thno.36739 · Cited by 90 · see citing works
Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy
Jannetti, S. A., Zeglis, B. M., Zalutsky, M. R., & Reiner, T. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00170 · Cited by 90 · see citing works
Carney, B. D., Kossatz, S., & Reiner, T. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.189936 · Cited by 88 · see citing works
A Single Dose of 225Ac-RPS-074 Induces a Complete Tumor Response in an LNCaP Xenograft Model
Kelly, J. M., Amor‐Coarasa, A., Ponnala, S., Nikolopoulou, A., Williams, C. M., Thiele, N. A., Schlyer, D. J., Wilson, J. J., DiMagno, S. G., & Babich, J. W. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.219592 · Cited by 87 · see citing works
Zhu, W., Cheng, Y., Wang, X., Yao, S., Bai, C., Zhao, H., Jia, R., Xu, J., & Huo, L. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.235093 · Cited by 87 · see citing works
Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window
Kelly, J. M., Amor‐Coarasa, A., Ponnala, S., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.221150 · Cited by 86 · see citing works
Harnessing α -Emitting Radionuclides for Therapy: Radiolabeling Method Review
Yang, H., Wilson, J. J., Orvig, C., Li, Y., Wilbur, D. S., Ramogida, C. F., Radchenko, V., & Schaffer, P. C. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262687 · Cited by 86 · see citing works
Highly Potent Cyclic Disulfide Antagonists of Somatostatin
Hocart, S. J., Jain, R., Murphy, W. A., Taylor, J. E., & Coy, D. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm9806289 · Cited by 85 · see citing works
Hobbs, R. F., Wahl, R. L., Lodge, M. A., et al. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.066738 · Cited by 85 · see citing works
Bluemel, C., Hahner, S., Heinze, B., Faßnacht, M., Kroiß, M., Bley, T. A., Wester, H., Kropf, S., Lapa, C., Schirbel, A., et al. (2016) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000001435 · Cited by 81 · see citing works
Kelly, J., Amor‐Coarasa, A., Ponnala, S., Nikolopoulou, A., Williams, C. M., Schlyer, D. J., Zhao, Y., Kim, D., & Babich, J. W. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4004-5 · Cited by 81 · see citing works
The Radiobiology of Radiopharmaceuticals
Morris, Z. S., Wang, A. Z., & Knox, S. J. (2020) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2020.07.002 · Cited by 81 · see citing works
Maung, J., Mallari, J. P., Girtsman, T., et al. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.06.031 · Cited by 79 · see citing works
Lewis, J. S., Windhorst, A. D., & Zeglis, B. M. (2019) · Springer eBooks · doi:10.1007/978-3-319-98947-1 · Cited by 78 · see citing works
Influence of Different Spacers on the Biological Profile of a DOTA−Somatostatin Analogue
Antunes, P., Ginj, M., Walter, M. A., et al. (2006) · Bioconjugate Chemistry · doi:10.1021/bc0601673 · Cited by 77 · see citing works
Dosimetry for Radiopharmaceutical Therapy: Current Practices and Commercial Resources
Capala, J., Graves, S. A., Aaron, S., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262749 · Cited by 75 · see citing works
Stallons, T. A. R., Saidi, A., Tworowska, I., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1103 · Cited by 74 · see citing works
A prostate-specific membrane antigen activated molecular rotor for real-time fluorescence imaging
Zhang, J., Rakhimbekova, A., Duan, X., Yin, Q., Foss, C. A., Fan, Y., Xu, Y., Li, X., Cai, X., Kutil, Z., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25746-6 · Cited by 74 · see citing works
Somatostatin Analogues for Somatostatin-Receptor-Mediated Radiotherapy of Cancer
Stolz, B., Smith-Jones, P. M., Albert, R., et al. (2009) · Digestion · doi:10.1159/000201387 · Cited by 72 · see citing works
Liu, G., Banerjee, S. R., Yang, X., Yadav, N. N., Lisok, A., Jabłońska, A., Xu, J., Li, Y., Pomper, M. G., & van Zijl, P. C. M. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0168-8 · Cited by 70 · see citing works
PARP-1–Targeted Radiotherapy in Mouse Models of Glioblastoma
Jannetti, S. A., Carlucci, G., Carney, B. D., Kossatz, S., Shenker, L., Carter, L. M., Salinas, B., Brand, C., Sadique, A., Donabedian, P. L., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.205054 · Cited by 70 · see citing works
Osl, T., Schmidt, A., Schwaiger, M., et al. (2020) · Theranostics · doi:10.7150/thno.45537 · Cited by 70 · see citing works
PARPi-FL - a Fluorescent PARP1 Inhibitor for Glioblastoma Imaging
Irwin, C. P., Portorreal, Y., Brand, C., Zhang, Y., Desai, P., Salinas, B., Weber, W., & Reiner, T. (2014) · Neoplasia · doi:10.1016/j.neo.2014.05.005 · Cited by 68 · see citing works
Herhaus, P., Habringer, S., Philipp‐Abbrederis, K., Vág, T., Gerngroß, C., Schottelius, M., Slotta‐Huspenina, J., Steiger, K., Altmann, T., Weißer, T., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.142976 · Cited by 67 · see citing works
Radioiodinated PARP1 tracers for glioblastoma imaging
Salinas, B., Irwin, C. P., Kossatz, S., Bolaender, A., Chiosis, G., Pillarsetty, N., Weber, W., & Reiner, T. (2015) · EJNMMI Research · doi:10.1186/s13550-015-0123-1 · Cited by 64 · see citing works
Klingler, M., Summer, D., Rangger, C. A., Haubner, R., Foster, J., Sosabowski, J. K., Decristoforo, C., Virgolini, I. J., & von Guggenberg, E. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.221283 · Cited by 64 · see citing works
Aptamers as radiopharmaceuticals for nuclear imaging and therapy
Gijs, M., Aerts, A., Impens, N. R. E. N., Baatout, S., & Luxen, A. (2015) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2015.09.005 · Cited by 63 · see citing works
PSMA specific antibodies and their diagnostic and therapeutic use
Holmes, E. H. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.3.511 · Cited by 60 · see citing works
Maffey-Steffan, J., Scarpa, L., Svirydenka, A., Nilica, B., Mair, C., Buxbaum, S., Bektić, J., von Guggenberg, E., Uprimny, C., Horninger, W., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04583-2 · Cited by 60 · see citing works
Sauter, A. W., Mansi, R., Hassiepen, U., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.207845 · Cited by 58 · see citing works
Imaging Tumor Angiogenesis: The Road to Clinical Utility
Iagaru, A. H., & Gambhir, S. S. (2013) · American Journal of Roentgenology · doi:10.2214/ajr.12.8568 · Cited by 57 · see citing works
Zhang, C., Zhang, Z., Lin, K., Pan, J., Dude, I., Hundal-Jabal, N., Colpo, N., & Bénard, F. (2017) · Theranostics · doi:10.7150/thno.17117 · Cited by 55 · see citing works
Makvandi, M., Lee, H., Puentes, L. N., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0837 · Cited by 55 · see citing works
Schulz, J., Rohracker, M., Stiebler, M., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.185140 · Cited by 54 · see citing works
Hu, K., Hanyu, M., Xie, L., et al. (2019) · Chemical Communications · doi:10.1039/c9cc00445a · Cited by 54 · see citing works
Self-citationTumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns.
Sgouros, G., Dewaraja, Y. K., Escorcia, F. E., Graves, S. A., Hope, T. A., Iravani, A., Pandit-Taskar, N. D., Saboury, B., James, S. S., & ZANZONICO, P. B. (2021) · PubMed Central · doi:10.2967/jnumed.121.262750 · Cited by 54 · see citing works
Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer
Siva, S., Udovicich, C., Tran, B., Zargar, H. S., Murphy, D. G., & Hofman, M. S. (2020) · Nature Reviews Urology · doi:10.1038/s41585-019-0272-5 · Cited by 53 · see citing works
Kelly, J., Amor‐Coarasa, A., Nikolopoulou, A., Kim, D., Williams, C. M., Ponnala, S., & Babich, J. W. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3556-5 · Cited by 51 · see citing works
Targeted Radionuclide Therapy: New Advances for Improvement of Patient Management and Response
Malcolm, J., Falzone, N., Lee, B. Q., & Vallis, K. A. (2019) · Cancers · doi:10.3390/cancers11020268 · Cited by 51 · see citing works
Pandit-Taskar, N. D., Iravani, A., Lee, D., Jacene, H. A., Pryma, D. A., Hope, T. A., Saboury, B., Capala, J., & Wahl, R. L. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262977 · Cited by 51 · see citing works
Novruzov, F., Aliyev, J. A., Jaunmuktane, Z., et al. (2014) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000000589 · Cited by 50 · see citing works
Theranostics in neuroendocrine tumors: an overview of current approaches and future challenges
Refardt, J. C., Hofland, J., Antwi, K., Nicolas, G. P., Rottenburger, C., Fani, M., Wild, D., & Christ, E. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09552-x · Cited by 50 · see citing works
Μάινα, Θ., Konijnenberg, M., Peitl, P. K., et al. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.05.011 · Cited by 49 · see citing works
Percent 131 I Uptake and Post-Therapy 131 I Scans: Their Role in the Management of Thyroid Cancer
Reynolds, J. C. (1997) · Thyroid · doi:10.1089/thy.1997.7.281 · Cited by 46 · see citing works
Dosimetry Estimate and Initial Clinical Experience with 90Y-PSMA-617
Rathke, H., Flechsig, P., Mier, W., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.218917 · Cited by 46 · see citing works
Hu, K., Wu, W., Xie, L., Geng, H. R., Zhang, Y., Hanyu, M., Zhang, L., Liu, Y., Nagatsu, K., Suzuki, H., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.09.016 · Cited by 46 · see citing works
Self-citationBorgna, F., Barritt, P., Grundler, P. V., Talip, Z., Cohrs, S., Zeevaart, J. R., Köster, U., Schibli, R., van der Meulen, N. P., & Müller, C. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040536 · Cited by 45 · see citing works
Xie, Q., Liu, T., Ding, J. L., Zhou, N., Meng, X., Zhu, H., Li, N., Yu, J., & Yang, Z. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05249-8 · Cited by 44 · see citing works
Wang, Y., Lomakin, A., Kanai, S., Alex, R., Belli, S., Donzelli, M., & Benedek, G. B. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.08.035 · Cited by 43 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation
Dhoundiyal, S., Srivastava, S., Kumar, S., Singh, G., Ashique, S., Pal, R., Mishra, N., & Taghizadeh-Hesary, F. (2024) · European Journal of Medical Research · doi:10.1186/s40001-023-01627-0 · Cited by 144 · see citing works
“In prostate cancer, radiolabelled antibodies like 177 Lu-PSMA-617 have emerged as potent tools, capitalizing on the overexpression of prostate-specific membrane antigen (PSMA) in prostate cancer cells [98], as depicted in Fig.”
Background
- Authors
- Sun, J., Huangfu, Z., Yang, J., Wang, G., Hu, K., Gao, M., & Zhong, Z.
- Affiliations
- Soochow University (CN)
- National Institutes for Quantum Science and Technology (JP)
- Corresponding author
- Wang, Guanglin
- Hu, Kuan
- Zhong, Zhiyuan
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2022-11
- Volume
- 190
- Pages
- 114538
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W4297014860
- Cited by
- 57
- References
- 242
- Citations by year
- 2026: 12 · 2025: 18 · 2024: 19 · 2023: 8
- FWCI
- 1.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Advanced Drug Delivery Reviews (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Health Sciences › Medicine › Epidemiology › Neuroendocrine Tumor Research Advances
- Keywords
- targeted radionuclide therapy, radiopharmaceuticals, radioligands, nuclear medicine, dosimetry, precision cancer therapy, prostate cancer, neuroendocrine tumors, molecular imaging, personalized medicine, clinical translation
- MeSH terms
- Humans, Iodine Radioisotopes, Male, Neoplasms, Sodium Iodide, Radiopharmaceuticals, Molecular Imaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
